Clene Inc. (CLNN) · Oct 19, 2026 · Material agreement
$7.2M fourth-year subaward — Up to $7.2M for September 2026–August 2027
Clene’s grant agreement adds up to $7.2 million for year four of its ALS access program, extending support without changing the core story.
Clene is a late-stage biotechnology company developing CNM-Au8 for ALS and other neurodegenerative diseases, with its near-term story centered on seeking accelerated approval in ALS.
The filing extends an existing support program rather than changing the development story. Clene signed the fourth-year amendment for up to $7.2 million covering September 1, 2026 through August 31, 2027. The direction was already largely visible: the company had previously disclosed a four-year, $45.1 million NIH grant and successive annual subawards, so this is mainly confirmation of the final planned funding period.
The money supports patient access and data collection, not a new efficacy or regulatory milestone. The grant funds an Expanded Access Program for CNM-Au8 in ALS. 〔0〕 That helps sustain the program while Clene pursues its NDA, but the amendment itself supplies no new clinical results, FDA decision, or change to the drug’s approval odds.
Bottom line: This is useful operational continuity for Clene’s ALS program, but not a meaningful change to the investment story. The grant renewal is partly known and largely confirms funding already embedded in the company’s plan.
FDA review of CNM-Au8 NDA
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!